Clinical Development of Solnatide Peptide for the Therapeutic Treatment of ARDS During the Coronavirus Pandemic
Time: 12:45 pm
day: Day Two
Details:
- Reviewing solnatide peptide and its capacity to activate pulmonary edema clearance and highlighting the molecular structure and interaction with the pulmonary ENaC channel
- Exploring basic characteristics of ARDS patients Vs. COVID-19 patients to illuminate whether ARDS pneumonia behaves similarly to viral/COVID pneumonia
- Navigating the limitation in hospital management during pandemics
- Delving into clinical trials to explore what lessons can be taken away from the pandemic
